Страна: Канада
мова: англійська
Джерело: Health Canada
METHOTREXATE (METHOTREXATE SODIUM)
APOTEX INC
L01BA01
METHOTREXATE
2.5MG
TABLET
METHOTREXATE (METHOTREXATE SODIUM) 2.5MG
ORAL
100
Prescription
ANTINEOPLASTIC AGENTS
Active ingredient group (AIG) number: 0107545001; AHFS:
APPROVED
2019-03-21
Page 1 of 42 PRODUCT MONOGRAPH PR METHOTREXATE Methotrexate Tablets USP 2.5 mg Methotrexate (as Methotrexate Sodium) Antimetabolite APOTEX INC. 150 Signet Drive Toronto, Ontario M9L 1T9 DATE OF REVISION: October 17, 2019 Submission Control No.: 231321 Page 2 of 42 TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ..............................................3 SUMMARY PRODUCT INFORMATION ........................................................................3 INDICATIONS AND CLINICAL USE ..............................................................................3 CONTRAINDICATIONS ...................................................................................................4 WARNINGS AND PRECAUTIONS .................................................................................4 ADVERSE REACTIONS ................................................................................................11 DRUG INTERACTIONS ..................................................................................................15 DOSAGE AND ADMINISTRATION .............................................................................19 OVERDOSAGE.................................................................................................................22 ACTION AND CLINICAL PHARMACOLOGY ...........................................................22 STORAGE AND STABILITY ..........................................................................................25 SPECIAL HANDLING INSTRUCTIONS ....................................................................25 DOSAGE FORMS, COMPOSITION AND PACKAGING ...........................................26 PART II: SCIENTIFIC INFORMATION ....................................................................27 PHARMACEUTICAL INFORMATION ..........................................................................27 CLINICAL TRIALS ..........................................................................................................27 DETAILED PHARMACOLOGY .................... Прочитайте повний документ